<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/1999/REC-html401-19991224/loose.dtd">
<html><head><title>Index for xtools.gsea.LeadingEdgeTool my_analysis.LeadingEdgeTool.1440023440057</title><link href='xtools.css' rel='stylesheet'><link href='http://www.broadinstitute.org/gsea/images/XBench.gif' rel='shortcut icon'></head><body><div id="footer" style="width: 905; height: 35">
<h3 style="text-align: left"><font color="#808080">Leading edge report for GSEA result folder: BenefitVsNoBenefit</font></h3>
</div><div><h4>Leading edge analysis: Clustered results</h4><ul><li>There were 53 gene sets used in the leading edge analysis (see below for details)<li><a href='leading_edge_heat_map_clustered.png'>Heat map of clustered leading edge subsets</a> . Rows are gene sets and columns are genes. This matrix is clustered</ul></div><br><div><h4>Details of gene sets and signals used in this analysis</h4><table><th><td># members</td><td># members<br>in signal</td><td>Tag %</td><td>List %</td><td>Signal strength</td></th><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_INTERFERON_GAMMA_RESPONSE.html'>HALLMARK_INTERFERON_GAMMA_RESPONSE</a></td><td>171</td><td>111</td><td>65%</td><td>16%</td><td>76%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_INTERFERON_ALPHA_RESPONSE.html'>HALLMARK_INTERFERON_ALPHA_RESPONSE</a></td><td>86</td><td>58</td><td>67%</td><td>16%</td><td>80%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ALLOGRAFT_REJECTION.html'>HALLMARK_ALLOGRAFT_REJECTION</a></td><td>137</td><td>55</td><td>40%</td><td>8%</td><td>43%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_INFLAMMATORY_RESPONSE.html'>HALLMARK_INFLAMMATORY_RESPONSE</a></td><td>133</td><td>62</td><td>47%</td><td>15%</td><td>54%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_COMPLEMENT.html'>HALLMARK_COMPLEMENT</a></td><td>141</td><td>58</td><td>41%</td><td>15%</td><td>48%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_IL6_JAK_STAT3_SIGNALING.html'>HALLMARK_IL6_JAK_STAT3_SIGNALING</a></td><td>65</td><td>30</td><td>46%</td><td>16%</td><td>54%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_XENOBIOTIC_METABOLISM.html'>HALLMARK_XENOBIOTIC_METABOLISM</a></td><td>132</td><td>37</td><td>28%</td><td>14%</td><td>32%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY.html'>HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY</a></td><td>44</td><td>22</td><td>50%</td><td>18%</td><td>61%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_TNFA_SIGNALING_VIA_NFKB.html'>HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></td><td>175</td><td>54</td><td>31%</td><td>15%</td><td>36%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_P53_PATHWAY.html'>HALLMARK_P53_PATHWAY</a></td><td>170</td><td>36</td><td>21%</td><td>8%</td><td>23%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_GLYCOLYSIS.html'>HALLMARK_GLYCOLYSIS</a></td><td>166</td><td>56</td><td>34%</td><td>17%</td><td>40%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_APOPTOSIS.html'>HALLMARK_APOPTOSIS</a></td><td>142</td><td>46</td><td>32%</td><td>17%</td><td>39%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_PROTEIN_SECRETION.html'>HALLMARK_PROTEIN_SECRETION</a></td><td>90</td><td>37</td><td>41%</td><td>21%</td><td>52%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_BILE_ACID_METABOLISM.html'>HALLMARK_BILE_ACID_METABOLISM</a></td><td>68</td><td>21</td><td>31%</td><td>13%</td><td>35%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_UV_RESPONSE_UP.html'>HALLMARK_UV_RESPONSE_UP</a></td><td>126</td><td>42</td><td>33%</td><td>17%</td><td>40%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_PEROXISOME.html'>HALLMARK_PEROXISOME</a></td><td>81</td><td>32</td><td>40%</td><td>20%</td><td>49%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_IL2_STAT5_SIGNALING.html'>HALLMARK_IL2_STAT5_SIGNALING</a></td><td>158</td><td>49</td><td>31%</td><td>16%</td><td>37%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ESTROGEN_RESPONSE_LATE.html'>HALLMARK_ESTROGEN_RESPONSE_LATE</a></td><td>133</td><td>27</td><td>20%</td><td>9%</td><td>22%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ADIPOGENESIS.html'>HALLMARK_ADIPOGENESIS</a></td><td>177</td><td>57</td><td>32%</td><td>17%</td><td>38%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_MTORC1_SIGNALING.html'>HALLMARK_MTORC1_SIGNALING</a></td><td>196</td><td>52</td><td>27%</td><td>15%</td><td>31%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ANDROGEN_RESPONSE.html'>HALLMARK_ANDROGEN_RESPONSE</a></td><td>86</td><td>19</td><td>22%</td><td>10%</td><td>24%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_KRAS_SIGNALING_UP.html'>HALLMARK_KRAS_SIGNALING_UP</a></td><td>141</td><td>35</td><td>25%</td><td>14%</td><td>28%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_COAGULATION.html'>HALLMARK_COAGULATION</a></td><td>84</td><td>24</td><td>29%</td><td>13%</td><td>33%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_FATTY_ACID_METABOLISM.html'>HALLMARK_FATTY_ACID_METABOLISM</a></td><td>128</td><td>33</td><td>26%</td><td>13%</td><td>29%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_KRAS_SIGNALING_DN.html'>HALLMARK_KRAS_SIGNALING_DN</a></td><td>54</td><td>13</td><td>24%</td><td>11%</td><td>27%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_HEME_METABOLISM.html'>HALLMARK_HEME_METABOLISM</a></td><td>153</td><td>45</td><td>29%</td><td>18%</td><td>35%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/CANCER_IMMUNITY_DIFFERENTIATION_ANTIGENS.html'>CANCER_IMMUNITY_DIFFERENTIATION_ANTIGENS</a></td><td>1</td><td>1</td><td>100%</td><td>9%</td><td>109%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_HYPOXIA.html'>HALLMARK_HYPOXIA</a></td><td>160</td><td>38</td><td>24%</td><td>15%</td><td>28%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_PI3K_AKT_MTOR_SIGNALING.html'>HALLMARK_PI3K_AKT_MTOR_SIGNALING</a></td><td>86</td><td>28</td><td>33%</td><td>18%</td><td>39%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ESTROGEN_RESPONSE_EARLY.html'>HALLMARK_ESTROGEN_RESPONSE_EARLY</a></td><td>140</td><td>23</td><td>16%</td><td>11%</td><td>18%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_OXIDATIVE_PHOSPHORYLATION.html'>HALLMARK_OXIDATIVE_PHOSPHORYLATION</a></td><td>196</td><td>44</td><td>22%</td><td>16%</td><td>26%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_CHOLESTEROL_HOMEOSTASIS.html'>HALLMARK_CHOLESTEROL_HOMEOSTASIS</a></td><td>67</td><td>10</td><td>15%</td><td>9%</td><td>16%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_PANCREAS_BETA_CELLS.html'>HALLMARK_PANCREAS_BETA_CELLS</a></td><td>10</td><td>3</td><td>30%</td><td>16%</td><td>36%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS.html'>CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS</a></td><td>27</td><td>4</td><td>15%</td><td>6%</td><td>16%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_APICAL_JUNCTION.html'>HALLMARK_APICAL_JUNCTION</a></td><td>136</td><td>14</td><td>10%</td><td>7%</td><td>11%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_SPERMATOGENESIS.html'>HALLMARK_SPERMATOGENESIS</a></td><td>64</td><td>19</td><td>30%</td><td>27%</td><td>41%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_APICAL_SURFACE.html'>HALLMARK_APICAL_SURFACE</a></td><td>29</td><td>5</td><td>17%</td><td>7%</td><td>18%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS.html'>CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS</a></td><td>2</td><td>1</td><td>50%</td><td>24%</td><td>66%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_HEDGEHOG_SIGNALING.html'>HALLMARK_HEDGEHOG_SIGNALING</a></td><td>24</td><td>11</td><td>46%</td><td>32%</td><td>67%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_MYC_TARGETS_V2.html'>HALLMARK_MYC_TARGETS_V2</a></td><td>58</td><td>29</td><td>50%</td><td>44%</td><td>89%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_DNA_REPAIR.html'>HALLMARK_DNA_REPAIR</a></td><td>136</td><td>53</td><td>39%</td><td>35%</td><td>59%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_G2M_CHECKPOINT.html'>HALLMARK_G2M_CHECKPOINT</a></td><td>194</td><td>104</td><td>54%</td><td>48%</td><td>102%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_UNFOLDED_PROTEIN_RESPONSE.html'>HALLMARK_UNFOLDED_PROTEIN_RESPONSE</a></td><td>107</td><td>39</td><td>36%</td><td>32%</td><td>54%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_MYC_TARGETS_V1.html'>HALLMARK_MYC_TARGETS_V1</a></td><td>197</td><td>97</td><td>49%</td><td>43%</td><td>85%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_MYOGENESIS.html'>HALLMARK_MYOGENESIS</a></td><td>118</td><td>50</td><td>42%</td><td>31%</td><td>61%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_E2F_TARGETS.html'>HALLMARK_E2F_TARGETS</a></td><td>193</td><td>92</td><td>48%</td><td>41%</td><td>80%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_UV_RESPONSE_DN.html'>HALLMARK_UV_RESPONSE_DN</a></td><td>127</td><td>36</td><td>28%</td><td>19%</td><td>35%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_MITOTIC_SPINDLE.html'>HALLMARK_MITOTIC_SPINDLE</a></td><td>196</td><td>108</td><td>55%</td><td>44%</td><td>96%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_WNT_BETA_CATENIN_SIGNALING.html'>HALLMARK_WNT_BETA_CATENIN_SIGNALING</a></td><td>35</td><td>11</td><td>31%</td><td>17%</td><td>38%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_TGF_BETA_SIGNALING.html'>HALLMARK_TGF_BETA_SIGNALING</a></td><td>51</td><td>21</td><td>41%</td><td>29%</td><td>58%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_ANGIOGENESIS.html'>HALLMARK_ANGIOGENESIS</a></td><td>25</td><td>9</td><td>36%</td><td>18%</td><td>44%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_NOTCH_SIGNALING.html'>HALLMARK_NOTCH_SIGNALING</a></td><td>29</td><td>15</td><td>52%</td><td>22%</td><td>66%</td></tr><tr><td><a href='file:/Users/arman/gsea_home/output/aug19/upload/BenefitVsNoBenefit/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION.html'>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a></td><td>158</td><td>85</td><td>54%</td><td>29%</td><td>75%</td></tr></table></div><br><div><h4>Leading edge analysis: other files made</h4><ul><li><a href='conv.gct'>Clustered dataset (gct)</a> for the specified gene sets. 1's denote membership of a gene in the leading edge subset<li><a href='leading_edge_matrix_for_results.gmx'>GeneSetMatrix (gmx)</a> of leading edge subsets<li><a href='leading_edge_matrix_for_results.4.gct'>Dataset (gct)</a> for the specified gene sets. 1's denote membership of a gene in the leading edge subset<li><a href='leading_edge_heat_map_unclustered.png'>Heat map of leading edge subsets</a> . Rows are gene sets and columns are genes. This matrix is NOT clustered</ul></div><br><div><h4>Other</h4><ul><li><a href='my_analysis.LeadingEdgeTool.1440023440057.rpt'>Parameters</a> used for this analysis</ul></div><div><br></div><hr class="solid_line"/>
<div id="footer">
Report: my_analysis.LeadingEdgeTool.1440023440057.rpt&nbsp&nbsp by user: arman&nbsp&nbsp<div class="date">xtools.gsea.LeadingEdgeTool&nbsp[Wed, Aug 19, '15 6 PM 30]</div>
<div class="contact">Website: <a href="http://www.broadinstitute.org/gsea">www.broadinstitute.org/GSEA</a>
Questions & Suggestions: <a href="mailto:gsea@broadinstitute.org">Email</a></div>
<div class="spacer">&nbsp;</div>
</div>
</body></html>